Importance of protocols for simulation studies in clinical drug development

Clinical trial simulation studies can be used to assess the impact of many aspects of trial design, conduct, analysis and decision making on trial performance metrics. Simulation studies can play a vital role in improving the efficiency of the drug development process within the pharmaceutical industry, but only if they are well designed and conducted. It is imperative therefore that a protocol or simulation plan is developed, documenting how the simulation study is to be conducted, analysed and reported. This article emphasises the specific considerations necessary for designing good quality simulation studies. These include defining data generation processes, data analytic methods, decision criteria and also determining the presentation of results for all intended audiences. With clinical trial simulations becoming a vital part of the drug development process, the protocol for clinical trial simulations may in future become part of the regulatory peer review process. More rigour in the planning and execution of simulation studies will ensure that the design, analysis and decision-making process for the subsequent clinical trial is based on credible evidence that can be independently verified.

[1]  Huei Wang,et al.  Performance of some multiple testing procedures to compare three doses of a test drug and placebo , 2005 .

[2]  Anthony C. Atkinson,et al.  Optimum Experimental Designs, with SAS , 2007 .

[3]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[4]  Roderick J. A. Little,et al.  Statistical Analysis with Missing Data , 1988 .

[5]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[6]  Peter L. Bonate.  Clinical Trial Simulation: Theory , 2006 .

[7]  W. J. Studden,et al.  Theory Of Optimal Experiments , 1972 .

[8]  Nicholas H. G. Holford,et al.  Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation , 2007, Pharmaceutical Research.

[9]  Yinghui Zhou,et al.  Gaining acceptability for the Bayesian decision‐theoretic approach in dose‐escalation studies , 2005 .

[10]  Per Olsson,et al.  Modelling and simulation to improve decision-making in clinical development , 2005 .

[11]  Patrick Royston,et al.  The design of simulation studies in medical statistics , 2006, Statistics in medicine.

[12]  Satoshi Morita,et al.  Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design , 2006, Pharmaceutical statistics.

[13]  Scott Marshall,et al.  A Bayesian Design and Analysis for Dose-Response Using Informative Prior Information , 2006, Journal of biopharmaceutical statistics.

[14]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[15]  Steven P. Millard,et al.  Applied Statistics in the Pharmaceutical Industry , 2010 .

[16]  Analysis of Analgesic Trials , 2001 .

[17]  J. Mandema,et al.  Use of Modeling and Simulation to Optimize Dose-Finding Strategies , 2002 .

[18]  G. Koch,et al.  Evaluation of a weighted multiple comparison procedure , 2005 .

[19]  Yonggang Lu,et al.  Clinical Trials Simulation: A Statistical Approach , 2008, Journal of biopharmaceutical statistics.

[20]  A. Brix.  Bayesian Data Analysis, 2nd edn , 2005 .

[21]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[22]  Nonlinear mixed effects modelling for estimation of steady state attainment , 2005 .

[23]  Pascal Girard,et al.  Clinical trial simulation: a tool for understanding study failures and preventing them. , 2005, Basic & clinical pharmacology & toxicology.

[24]  Richard A. Vollenweider,et al.  Input-output models , 1975, Schweizerische Zeitschrift für Hydrologie.

[25]  Paul J. Williams,et al.  Modeling and Simulation: Planning and Execution , 2006 .

[26]  Anthony O'Hagan,et al.  Assurance in clinical trial design , 2005 .

[27]  Peter F. Thall,et al.  Bayesian Clinical Trial Design in a Cancer Center , 2001 .

[28]  Amit Roy,et al.  Physiologically Based Pharmacokinetic Modeling: Inhalation, Ingestion, and Dermal Absorption , 2006 .

[29]  L. Aarons,et al.  Model-based Integration for Clinical Trial Simulation and Design: A Phase ll Case Study for Naratriptan , 2003 .

[31]  Andrew P Grieve,et al.  Implementation of a Bayesian adaptive design in a proof of concept study , 2006, Pharmaceutical statistics.

[32]  I. Lipkovich,et al.  Multiple imputation compared with restricted pseudo‐likelihood and generalized estimating equations for analysis of binary repeated measures in clinical studies , 2005 .

[33]  Allan Donner,et al.  The impact of missing values in the concentration–time curve on the assessment of bioequivalence , 2005 .

[34]  Vikram Sinha,et al.  Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation , 2005, The AAPS Journal.

[35]  Modeling and Simulation to Support Dose Selection and Clinical Development of SC‐75416, a Selective COX‐2 Inhibitor for the Treatment of Acute and Chronic Pain , 2008, Clinical pharmacology and therapeutics.